

# **2024-2029 Estonia Therapeutic Drug Monitoring (TDM) Market Assessment for 28 Assays--2024 Supplier Shares and 2024-2029 Segment Forecasts by Test, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities for Suppliers**

<https://marketpublishers.com/r/2C331E46DFFBEN.html>

Date: October 2024

Pages: 0

Price: US\$ 1,500.00 (Single User License)

ID: 2C331E46DFFBEN

## **Abstracts**

This unique report from LeadingMarketResearch.com provides information and analysis not available from any other published source. The report is available by section, and can be customized to specific information needs and budget. This new report from LeadingMarketResearch.com provides a comprehensive analysis of the therapeutic drug monitoring market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers. The report provides test volume and sales forecasts by market segment for the following assays: Amikacin, Apixaban, Argatroban, Betrixaban, Carbamazepine, Cyclosporin, Dabigatran, Digoxin, Edoxaban, Everolimus, Fluindione, Gentamicin, Levetiracetam, Lithium, Methotrexate, NAPA/Procainamide, Phenobarbital, Phenytoin, Quinidine, Rivaroxaban, Sirolimus, Tacrolimus, Theophylline, Tobramycin, Topirimate, Valproic Acid, Vancomycin, and Warfarin. During the next five years, the TDM market will undergo significant transformation. These changes will be caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. Some segments will start resembling commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others. This report is a unique market and technology assessment designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities and developed effective strategic responses. The study provides five-year forecasts for major TDM assays; compares

features of leading analyzers; and profiles key competitors.

## Contents

Introduction

Market and Technology Overview

A. Major Therapeutic Drug Monitoring Tests

### **1. OVERVIEW**

### **2. AMIKACIN**

### **3. APIXABAN**

### **4. ARGATROBAN**

### **5. BETRIXABAN**

### **6. CARBAMAZEPINE**

### **7. CYCLOSPORIN**

### **8. DABIGATRAN**

### **9. DIGOXIN**

### **10. EDOXABAN**

### **11. EVEROLIMUS**

### **12. FLUINDIONE**

### **13. GENTAMICIN**

### **14. LEVETIRACETAM**

### **15. LITHIUM**

### **16. METHOTREXATE**

**17. NAPA/PROCAINAMIDE**

**18. PHENOBARBITAL**

**19. PHENYTOIN**

**20. QUINIDINE**

**21. RIVAROXABAN**

**22. SIROLIMUS**

**23. TACROLIMUS**

**24. THEOPHYLLINE**

**25. TOBRAMYCIN**

**26. TOPIRIMATE**

**27. VALPROIC ACID**

**28. VANCOMYCIN**

**29. WARFARIN**

B. Instrumentation Review: Operating characteristics and features of high-, medium-, and low-volume/POC analyzers manufactured by Abaxis, Abbott, Alere/Inverness, Alfa Wassermann, AMS, Awareness Technologies, Beckman Coulter/Olympus, Binding Site, bioMérieux, Carolina Chemistries, DiaSorin, Grifols, Horiba, Medica, Nova Biomedical, Ortho-Clinical Diagnostics, Polymedco, Randox, Roche, Siemens, Tosoh, Vital Diagnostics and other suppliers

Table of Contents (Continued)

C. Major In Vitro Diagnostic Technologies

And Their Potential Applications

## **1. MONOCLONAL AND POLYCLONAL ANTIBODIES**

## **2. IMMUNOASSAYS**

- a. Technological Principle
- d. Chemiluminescence
- c. Enzyme Immunoassays (EIA)
  - Overview
  - ELISA
  - EMIT
  - Electrochemical
- d. Radioimmunoassays (RIA)
- e. Immunoprecipitation
- f. Affinity Chromatography

## **3. TANDEM MASS SPEC**

## **4. IT AND AUTOMATION**

## **5. DRY CHEMISTRY**

## **6. BIOSENSORS**

- D. Market Size, Growth and Major Supplier Shares
- Alternative Market Penetration Strategies
- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies for Decentralized Testing Markets

## **1. MARKETING APPROACHES**

## **2. PRODUCT COMPLEXITY**

## **3. CUSTOMER PREFERENCE**

## **4. ESTABLISHED SUPPLIERS**

## **5. EMERGING SUPPLIERS**

## 6. MAJOR TYPES OF DISTRIBUTORS

## 7. MARKET SEGMENTATION

Table of Contents (Continued)

Potential Market Entry Barriers and Risks

A. Market Maturity

B. Cost Containment

C. Competition

D. Technological Edge and Limitations

E. Patent Protection

F. Regulatory Constraints

G. Decentralized Testing Market Challenges

Competitive Assessments

Abbott

Agilent Technologies

Beckman Coulter/Danaher

bioMerieux

Bio-Rad

DiaSorin

Eiken Chemical

Fujirebio

Grifols

IL/Werfen

Kyowa Medex

Ortho-Clinical Diagnostics

PerkinElmer

Quest Diagnostics

Roche

Siemens Healthineers

Sysmex

Thermo Fisher

Tosoh

Wako

## I would like to order

Product name: 2024-2029 Estonia Therapeutic Drug Monitoring (TDM) Market Assessment for 28 Assays--2024 Supplier Shares and 2024-2029 Segment Forecasts by Test, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities for Suppliers

Product link: <https://marketpublishers.com/r/2C331E46DFFBEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2C331E46DFFBEN.html>